Publications by authors named "D A Alexoff"
Article Synopsis
- Bisphosphonates are crucial for treating bone tumors by preventing bone loss; this study explores the effectiveness of a new bisphosphonate, [Lu]Lu-P15-073, in radioligand therapy for bone metastases.
- Ten patients aged 35 to 75 with bone metastases received a single dose of [Lu]Lu-P15-073, showing rapid accumulation in tumors and minimal impact on other organs, while demonstrating safety through blood tests and pain assessments.
- The results indicate that the treatment was well-tolerated, significantly reduced pain in most patients, and suggests that [Lu]Lu-P15-073 could be a promising option for managing bone metastases.
Article Synopsis
- D6-[F]FP-(+)-DTBZ is a new imaging agent designed for PET scans that helps diagnose Parkinson's disease (PD) by tracking VMAT2 transporters in the brain.
- In a study, this radioligand demonstrated efficient production, high purity, and distinct uptake in brain regions associated with PD, showing a greater effectiveness compared to its non-deuterated counterpart.
- The findings suggest that D6-[F]FP-(+)-DTBZ could serve as a safer, more effective tool for monitoring VMAT2 levels in monoamine neurons, potentially improving PD diagnosis.
Purpose: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [Lu]Lu-P17-087, and its albumin binder modified derivative, [Lu]Lu-P17-088, were evaluated in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary endpoint was dosimetry evaluation, the second endpoint was radiation toxicity assessment (CTCAE 5.
View Article and Find Full Text PDFBone metastasis in cancer patients is a major disease advancement for various types of cancer. Previously, [Ga]Ga-HBED-CC-bisphosphonate ([Ga]Ga-P15-041) showed excellent bone uptake and efficient detection of bone metastasis in patients. To accommodate different α- or β-emitting metals for radionuclide therapy, a novel DOTA-HBED-CC-bisphosphonate (P15-073, ) was prepared and the corresponding [Ga]Ga- and [Lu]Lu- were successfully synthesized in high yields and purity.
View Article and Find Full Text PDFArticle Synopsis
- Recent advancements in PSMA-targeted radiopharmaceuticals, specifically [F]AlF-P16-093, have improved PET imaging for prostate cancer, enhancing accuracy in staging the disease.
- A custom automated synthesis platform produced over 15 GBq of [F]AlF-P16-093, achieving a radiochemical yield of about 52% and high purity.
- The final product formulation shows stability, with a minimal decline in radiochemical purity when stored correctly, indicating potential for clinical use.